AB Science Secures Japanese Patent for Masitinib in Multiple Sclerosis

AB Science SA has announced that Japan has granted a patent for the use of masitinib in treating progressive forms of multiple sclerosis (MS). This patent ensures protection until 2041, marking the first such recognition for masitinib in MS. The compound is noted for its unique mechanism targeting microglia and mast cells, crucial in progressive MS forms.

Masitinib has shown promising results in phase 2b/3 and ongoing phase 3 trials, indicating a significant reduction in disability progression and improved patient outcomes. The safety profile, affirmed through trials involving over 4,300 patients, aligns with previous risk assessments, showing no increased infection risks.

AB Science is pursuing similar patent protections globally across various diseases, including ALS and Alzheimer's, aiming to fulfill unmet medical needs in progressive MS cases, where existing treatments primarily target relapsing forms.